Research Program Overview
Thromboembolism in children with cancer: Although a well-known association in adults, the epidemiology and exact pathogenesis of thrombosis in association with children and cancer have not yet been clearly defined. So far there are no evidence-based guidelines for prevention or treatment of thrombosis in children with cancer. At McMaster University, my research focus is to evaluate epidemiology, risk factors predisposing to thrombosis and development of preventive and therapeutic strategies for thrombosis in children with cancer. I published a three-part review evaluating the epidemiology and pathogenesis of thrombosis in children with ALL in the context of the disease, therapy and inherited and acquired prothrombotic defects. (Thrombosis Research 2003; 111: 125-31; Thrombosis Research 2003; 111:119-212; Thrombosis Research 2003; 111:321-27). My study analysis of our institution's experience of thrombosis in children treated on Dana-Farber Cancer Institute ALL study protocols for the first time identified older age and high-risk ALL as risk factors for thrombosis. These findings have been presented in international conferences (J Clin Oncol 2004; 23:801; Med Ped Oncol 203; 41:310) and published in peer-review journal (British Journal of Haematology 2005, 129:803-10). I was invited to write literature review on thromboembolism in children with cancer. These reviews have identified the gaps in knowledge and areas of care that need to be addressed in the management of thrombosis in pediatric cancer patients (Thrombosis research 2006, 118:137-52; Seminars in Thrombosis and Hemostasis, 2007; 33:408-15). My epidemiological studies have shown that thrombosis is also a common complication in children with other types of cancer, namely sarcoma and lymphoma. Overall adolescents and children with mediashinal mass or pulmonary disease are at increased risk of TE (Pediatric Blood & Cancer 2006, 49:171-6; Thrombosis Research Accepted 2007; Pediatric Blood & Cancer Submitted 2008). My current research aims at comprehensive evaluation of prothrombotic risk factors predisposing to thrombosis in children with cancer and to develop a predictive model to identify patients at high risk for thrombosis.
- Comprehensive evaluation for risk factors predisposing pediatric cancer patient to the development of thromboembolism.
- Treatment of childhood and adult acute lymphoblastic leukemia
- Evaluation for inherited & acquired prothrombolic defects predisposing to symptomatic thromboembolism in children with acute lymphoblastic leukemia.
Publications & Achievements
Phone: 905-521-2100 x73431
Title: Administrative Assistant
Phone: 905-521-2100 x73673
Title: Clinical Research Associate